title: Relationship between levels of angiogenic and lymphangiogenic factors and the endoscopic, histological and clinical activity, and acute-phase reactants in patients with inflammatory bowel disease.
abstract: BACKGROUND
  Angiogenic and lymphangiogenic factors (ALFs) may play an important role in inflammatory bowel disease (IBD). Our aims were to evaluate levels of ALFs in serum and the colonic mucosa culture supernatant (MCS) of patients with active and quiescent IBD and healthy subjects and to correlate them with the endoscopic, clinical and histological activity and with acute-phase reactants.
  
  
  METHODS
  This is a prospective study of 28 controls and 72 IBD patients. Serum and MCS concentration of VEGFA, VEGFC, VEGFD, VEGFR1, VEGFR2, VEGFR3, PlGF, Ang1, Ang2 and Tie2 were measured by ELISA. Activity was established by specific indexes (CDAI, Mayo score, SES-CD, D'Haens scale and Riley index). Acute-phase reactants were routinely measured.
  
  
  RESULTS
  MCS levels of all ALFs except VEGFR3 were higher in patients with endoscopic (p<0.05), clinical (p<0.05) and histological (p<0.01) activity than in those without it. In serum, VEGFA, VEGFC and Ang1 and VEGFA and Ang1 levels were lower in patients in remission than in patients with clinical and histological activity, respectively (p<0.05). There was a correlation between serum and MCS concentrations for VEGFD, VEGFR3, PlGF and Tie2 (r=0.25, r=0.48, r=-0.45 and r=0.36; p<0.05). Ang2 in MCS was the best predictor for the diagnosis of endoscopic, histological and clinical activity (area under ROC curve>0.8).
  
  
  CONCLUSIONS
  MCS determination suggests a local increase in ALFs that correlates with IBD activity. Although the correlation between ALFs in serum and MCS was not good, the study of some of these factors as possible targets of new drugs for IBD constitutes a key new line of research.
authors: Department of Gastroenterology of the Hospital Universitario de Fuenlabrada, Madrid, Spain. Electronic address: alicia_algaba@hotmail.com.
authors: Alicia
authors: A
authors: Algaba
authors: Pablo M
authors: PM
authors: Linares
authors: M Encarnación
authors: ME
authors: Fernández-Contreras
authors: Amparo
authors: A
authors: Ordoñez
authors: Javier
authors: J
authors: Trápaga
authors: Iván
authors: I
authors: Guerra
authors: María
authors: M
authors: Chaparro
authors: Gema
authors: G
authors: de la Poza
authors: Javier P
authors: JP
authors: Gisbert
authors: Fernando
authors: F
authors: Bermejo
mesh_terms: D000209:Acute-Phase Proteins / Q000032:analysis / Q000378:metabolism*; D043925:Angiogenesis Inducing Agents; D042682:Angiopoietins / Q000032:analysis / Q000097:blood*; D015415:Biomarkers / Q000032:analysis / Q000097:blood; D001707:Biopsy, Needle; D016022:Case-Control Studies; D003093:Colitis, Ulcerative / Q000097:blood / Q000473:pathology / Q000503:physiopathology; D003424:Crohn Disease / Q000097:blood / Q000473:pathology / Q000503:physiopathology; D018450:Disease Progression; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D015212:Inflammatory Bowel Diseases / Q000097:blood* / Q000473:pathology* / Q000503:physiopathology; D007413:Intestinal Mucosa / Q000378:metabolism / Q000473:pathology; D042583:Lymphangiogenesis / Q000502:physiology*; D008297:Male; D016011:Normal Distribution; D011379:Prognosis; D011446:Prospective Studies; D012372:ROC Curve; D012307:Risk Factors; D012680:Sensitivity and Specificity; D012720:Severity of Illness Index; D018709:Statistics, Nonparametric; D042461:Vascular Endothelial Growth Factor A / Q000032:analysis / Q000378:metabolism*
chemical_list: D000209:Acute-Phase Proteins; D043925:Angiogenesis Inducing Agents; D042682:Angiopoietins; D015415:Biomarkers; D042461:Vascular Endothelial Growth Factor A
keywords: Angiogenesis; Angiogenic and lymphangiogenic factors; Inflammatory bowel disease; Lymphangiogenesis; Vascular endothelial growth factor